76 related articles for article (PubMed ID: 24785737)
1. Therapeutic alpha-interferons protein: structure, production, and biosimilar.
El-Baky NA; Redwan EM
Prep Biochem Biotechnol; 2015; 45(2):109-27. PubMed ID: 24785737
[TBL] [Abstract][Full Text] [Related]
2. Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha.
Alvarado Esquivel C; Elewaut A; Philippé J; Elewaut AE; Desombere I; Maertens G; Leroux-Roels G
Rev Invest Clin; 2002; 54(1):41-50. PubMed ID: 11995406
[TBL] [Abstract][Full Text] [Related]
3. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
[TBL] [Abstract][Full Text] [Related]
4. Antiviral activity of the interferon α family: biological and pharmacological aspects of the treatment of chronic hepatitis C.
Scagnolari C; Antonelli G
Expert Opin Biol Ther; 2013 May; 13(5):693-711. PubMed ID: 23350850
[TBL] [Abstract][Full Text] [Related]
5. Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the food and drug administration adverse event reporting system and review of the literature.
Salk A; Stobaugh DJ; Deepak P; Ehrenpreis ED
Ann Pharmacother; 2013 Apr; 47(4):537-42. PubMed ID: 23535814
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
[TBL] [Abstract][Full Text] [Related]
7. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.
Qashqari H; Al-Mars A; Chaudhary A; Abuzenadah A; Damanhouri G; Alqahtani M; Mahmoud M; El Sayed Zaki M; Fatima K; Qadri I
Infect Genet Evol; 2013 Oct; 19():113-9. PubMed ID: 23831932
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus: standard-of-care treatment.
Pawlotsky JM
Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
[TBL] [Abstract][Full Text] [Related]
9. [Alpha interferons--new therapeutic modalities].
Bajcetić M; Zigon N; Samardzić R; Beleslin DB
Med Pregl; 1998; 51(3-4):135-9. PubMed ID: 9611956
[TBL] [Abstract][Full Text] [Related]
10. [A trial of new interferon therapy for the patients with chronic hepatitis C resistant to interferon therapy].
Arase Y; Kumada H
Nihon Rinsho; 2001 Jul; 59(7):1309-14. PubMed ID: 11494543
[TBL] [Abstract][Full Text] [Related]
11. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus replication in mouse cells is restricted by IFN-dependent and -independent mechanisms.
Nandakumar R; Finsterbusch K; Lipps C; Neumann B; Grashoff M; Nair S; Hochnadel I; Lienenklaus S; Wappler I; Steinmann E; Hauser H; Pietschmann T; Kröger A
Gastroenterology; 2013 Dec; 145(6):1414-23.e1. PubMed ID: 23973921
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation.
Casanovas-Taltavull T; Baliellas C; Benasco C; Serrano TT; Casanova A; Pérez JL; Guerrero L; González MT; Andres E; Gil-Vernet S; Casais LA
Am J Gastroenterol; 2001 Apr; 96(4):1170-7. PubMed ID: 11316166
[TBL] [Abstract][Full Text] [Related]
14. Liver expression of proteins controlling interferon-mediated signalling as predictive factors in the response to therapy in patients with hepatitis C virus infection.
Bautista D; Bermúdez-Silva FJ; Lasarte JJ; Rodriguez-Fonseca F; Baixeras E
J Pathol; 2007 Nov; 213(3):347-55. PubMed ID: 17940994
[TBL] [Abstract][Full Text] [Related]
15. ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment.
Chen L; Sun J; Meng L; Heathcote J; Edwards AM; McGilvray ID
J Gen Virol; 2010 Feb; 91(Pt 2):382-8. PubMed ID: 19846672
[TBL] [Abstract][Full Text] [Related]
16. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
[TBL] [Abstract][Full Text] [Related]
17. Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication.
Metz P; Dazert E; Ruggieri A; Mazur J; Kaderali L; Kaul A; Zeuge U; Windisch MP; Trippler M; Lohmann V; Binder M; Frese M; Bartenschlager R
Hepatology; 2012 Dec; 56(6):2082-93. PubMed ID: 22711689
[TBL] [Abstract][Full Text] [Related]
18. MxA gene expression in peripheral blood mononuclear cells from patients infected chronically with hepatitis C virus treated with interferon-alpha.
Meier V; Mihm S; Ramadori G
J Med Virol; 2000 Nov; 62(3):318-26. PubMed ID: 11055241
[TBL] [Abstract][Full Text] [Related]
19. Human consensus interferons: Bridging the natural and artificial cytokines with intrinsic disorder.
El-Baky NA; Uversky VN; Redwan EM
Cytokine Growth Factor Rev; 2015 Dec; 26(6):637-45. PubMed ID: 26169931
[TBL] [Abstract][Full Text] [Related]
20. High efficiency targeting of IFN-α activity: possible applications in fighting tumours and infections.
Uzé G; Tavernier J
Cytokine Growth Factor Rev; 2015 Apr; 26(2):179-82. PubMed ID: 25466630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
